Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for-MedSci.cn

Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for

Shin, B; Ge, S; Petrosyan, A; Ammerman, NF; Vo, AA; Jordan, SC; Toyoda, M

AMERICAN JOURNAL OF TRANSPLANTATION, 2019; 19 (): 452

科室
- - 订阅+
  - 更多科室
工具
服务